We are live on
!
Find out more
FCM
Farallon Capital Management Portfolio holdings
AUM
$17.5B
1-Year Est. Return
50.95%
This Fund
S&P 500
This Quarter
Est. Return
+13.5%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$21.9B
AUM Growth
+$430M
(+2%)
Cap. Flow
-$2.03B
Cap. Flow
% of AUM
-9.27%
Top 10 Holdings %
Top 10 Hldgs %
51.69%
Holding
190
New
27
Increased
30
Reduced
39
Closed
32
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$731M |
| 2 |
HES
Hess
HES
|
+$436M |
| 3 |
Nasdaq
NDAQ
|
+$341M |
| 4 |
SPLK
Splunk Inc
SPLK
|
+$157M |
| 5 |
United Therapeutics
UTHR
|
+$110M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ATVI
Activision Blizzard
ATVI
|
+$1.9B |
| 2 |
VMW
VMware, Inc
VMW
|
+$915M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$770M |
| 4 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$482M |
| 5 |
Aon
AON
|
+$216M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 27.49% |
| 2 | Technology | 11.1% |
| 3 | Financials | 9.67% |
| 4 | Industrials | 6.16% |
| 5 | Communication Services | 5.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Charles River Laboratories
CRL
$12.8B
| $473K | ﹤0.01% |
2,000
-144,000
| -99% | -$28.3M |
|
102
Lufax Holding
LU
$1.3B
| $460K | ﹤0.01% |
149,999
-1
| -0% | -$4 |
|
103
BioNTech
BNTX
$23.5B
| $406K | ﹤0.01% |
3,844
| – | – |
|
104
Alnylam Pharmaceuticals
ALNY
$29.3B
| $383K | ﹤0.01% |
2,000
| – | – |
|
105
Altimmune
ALT
$599M
| $383K | ﹤0.01% |
+34,000
| New | +$142K |
|
106
Hims & Hers Health
HIMS
$7.31B
| $374K | ﹤0.01% |
42,000
| – | – |
|
|
BPMC
107
DELISTED
Blueprint Medicines
BPMC
| $369K | ﹤0.01% |
4,000
| – | – |
|
|
APLS
108
DELISTED
Apellis Pharmaceuticals
APLS
| $359K | ﹤0.01% |
6,000
-188,053
| -97% | -$9.54M |
|
109
Axsome Therapeutics
AXSM
$10.9B
| $318K | ﹤0.01% |
4,000
-121,653
| -97% | -$8.13M |
|
110
Krystal Biotech
KRYS
$9.66B
| $248K | ﹤0.01% |
2,000
| – | – |
|
111
BridgeBio Pharma
BBIO
$16.5B
| $242K | ﹤0.01% |
+6,000
| New | +$180K |
|
112
Chemed
CHE
$7.22B
| $234K | ﹤0.01% |
400
| – | – |
|
|
FOLD
113
DELISTED
Amicus Therapeutics
FOLD
| $227K | ﹤0.01% |
16,000
| – | – |
|
|
ACLX
114
DELISTED
Arcellx
ACLX
| $222K | ﹤0.01% |
+4,000
| New | +$180K |
|
115
Bruker
BRKR
$8.14B
| $220K | ﹤0.01% |
+3,000
| New | +$192K |
|
116
Acadia Healthcare
ACHC
$2.94B
| $218K | ﹤0.01% |
+2,800
| New | +$207K |
|
117
Syndax Pharmaceuticals
SNDX
$1.82B
| $216K | ﹤0.01% |
+10,000
| New | +$154K |
|
118
Vaxcyte
PCVX
$8.64B
| $214K | ﹤0.01% |
+3,400
| New | +$177K |
|
119
Glaukos
GKOS
$10.6B
| $207K | ﹤0.01% |
+2,600
| New | +$177K |
|
120
MoonLake Immunotherapeutics
MLTX
$1.55B
| $205K | ﹤0.01% |
+3,400
| New | +$175K |
|
121
Integra LifeSciences
IART
$1.34B
| $200K | ﹤0.01% |
+4,600
| New | +$181K |
|
122
Encompass Health
EHC
$12.4B
| $200K | ﹤0.01% |
3,000
| – | – |
|
123
Sabra Healthcare REIT
SBRA
$5.37B
| $200K | ﹤0.01% |
+14,000
| New | +$199K |
|
|
LUNRW
124
DELISTED
Intuitive Machines, Inc. Warrants
LUNRW
| $181K | ﹤0.01% |
950,000
| – | – |
|
|
RCM
125
DELISTED
R1 RCM Inc. Common Stock
RCM
| $169K | ﹤0.01% |
16,000
+4,000
| +33% | +$45.4K |
|
Similar funds
BBA
MCM
LA
CM
ASRS
PP
VMPIC
HNB
Farallon Capital Management's Q4 2023 Portfolio in Review
As of Q4 2023, Farallon Capital Management held 190 positions worth $21.9B, up 2% from $21.4B the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Farallon Capital Management withdrew a net $2.03B in Q4 2023, closing 32 positions and reducing 39 holdings. Its most notable exit was Activision Blizzard, an estimated $1.9B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 27% of assets, down from 31% a quarter earlier, followed by Technology and Financials.
Against the trend, Farallon Capital Management opened a new position in Pioneer Natural Resource Co. worth $702M.
- Farallon Capital Management's largest Q4 2023 buy was Pioneer Natural Resource Co.: 3,120,000 shares worth $702M.
- Farallon Capital Management added most to Nasdaq in Q4 2023, an estimated $341M increase.
- Farallon Capital Management's biggest Q4 2023 reduction was AstraZeneca, cutting an estimated $145M.
- Farallon Capital Management fully exited Activision Blizzard in Q4 2023, selling an estimated $1.9B.
- Farallon Capital Management's ten largest holdings make up 52% of its $21.9B portfolio in Q4 2023.
- Farallon Capital Management opened 27 new positions and closed 32 in Q4 2023.
- Farallon Capital Management's portfolio value rose 2% quarter-over-quarter to $21.9B.
Based on Farallon Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.